A new herpes zoster (HZ) subunit vaccine (HZ/su) appears to be more effective especially among elderly and longer duration of protection and less costly than the currently used live attenuated HZ vaccine (ZVL) at all ages, a new study published online January 2 in JAMA Internal Medicine shows. The US Food and Drug Administration (FDA) approved the...